Search results
Results From The WOW.Com Content Network
As the negative feedback of estrogen is inhibited, the hypothalamus secretes GnRh which in turn stimulates the anterior pituitary to secrete LH and FSH which help in ovulation. Between 60 and 85% of women, mostly with polycystic ovary syndrome (PCOS), ovulate successfully in response to clomiphene with a cumulative pregnancy rate of 30 to 40%.
Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take fertility medication to stimulate egg growth, and in other women in sporadic cases. Most cases are mild, but rarely the condition is severe and can lead to serious illness or even death.
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
Hormonal therapies to reduce or stop menstrual bleeding have long been used to manage a number of gynecologic conditions including menstrual cramps (dysmenorrhea), heavy menstrual bleeding, irregular or other abnormal uterine bleeding, menstrual-related mood changes (premenstrual syndrome or premenstrual dysphoric disorder), and pelvic pain due to endometriosis or uterine fibroids.
Ovulatory disorders result in infrequent ovulation (Oligoovulation) or absent ovulation (anovulation) which causes infertility. The World Health Organisation (WHO) has classified anovulation into three main classes, which are hypogonadotropic hypogonadal anovulation (Class 1), normogonadotropic normoestrogenic anovulation (Class 2), and hypergonadotropic hypoestrogenic anovulation (Class 3).
In the UK, one survey demonstrated that in 2010–2012, more than 33% of women aged 16–44 years had used oral contraception in the previous year and that it was mostly the combined type. [1] Between 2006 and 2010 only 10% of women in the US had used the contraceptive patch, and 6% had used the vaginal ring.
Ganirelix is used as a fertility treatment drug for women. Specifically, it is used to prevent premature ovulation in people with ovaries undergoing fertility treatment involving ovarian hyperstimulation that causes the ovaries to produce multiple eggs.
In ovarian hyperstimulation combined with IUI, women aged 38–39 years appear to have reasonable success during the first two cycles, with an overall live birth rate of 6.1% per cycle. [12] However, for women aged ≥40 years, the overall live birth rate is 2.0% per cycle, and there appears to be no benefit after a single cycle of COH/IUI. [12]